Latest News & Features
Generics
The UK High Court has refused to invalidate an Alcon glaucoma treatment patent in a judgment handed down on Friday, April 23. 27 April 2021
Big Pharma
Pfizer has discovered counterfeit versions of its COVID-19 vaccine in Mexico and Poland, prompting governments to reassure the public over the safety of vaccine supply chains. 27 April 2021
Big Pharma
The US Supreme Court heard oral arguments in Minerva Surgical v Hologic yesterday to discuss the potential abandoning of assignor estoppel. 22 April 2021
Americas
In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years. 22 April 2021
article
Now the race for the vaccine has been won, and we have 3 working vaccines. The next major battle against Covid-19 is the successful distribution of them. Major pharmaceutical companies came together collaboratively to win the first battle, so why is the second proving so hard? 22 April 2021
Americas
L’Oreal has secured a victory after a US federal court ruled that the French cosmetics brand did not infringe patents owned by the University of Massachusetts because they were invalid. 22 April 2021
article
The law of innovation balances private returns on investment against benefits to the public. Increasing the profitability of intellectual property acts as an inducement to spend money on research and testing, but threatens to increase costs to the public both directly and in terms of reduced access. 21 April 2021
Americas
Law firm Withers has expanded its US tech practice with the hire of a new team of life sciences and venture capital-focused lawyers in Boston. 20 April 2021
Plant Varieties
Just under a decade ago, Washington became the first state to legalise recreational cannabis, bringing with it the potential to create a legitimate business focused on the buying, selling or distribution of the drug in the US. 20 April 2021
Big Pharma
Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR. 20 April 2021